Dr Reddy’s Laboratories has acquired the trademarks for Progynova and Cyclo-Progynova in the Indian market from UK-headquartered Mercury Pharma Group Ltd (MPGL) for $32.15 million. This deal marks the pharma major’s entry into the hormone replacement therapy (HRT) segment and aims to strengthen its existing gynaecology portfolio in India. Shares of Dr Reddy’s slipped 0.32 percent on Wednesday, settling at Rs 1280.85 on the BSE.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Dr Reddy's Labs shares in focus as pharma major inks $32 million deal; key details
Dr Reddy’s Laboratories has acquired the trademarks for Progynova and Cyclo-Progynova in the Indian market from UK-headquartered Mercury Pharma Group Ltd (MPGL) for $32.15 million. This deal marks the pharma major’s entry into the hormone replacement therapy (HRT) segment and aims to strengthen its existing gynaecology portfolio in India. Shares of Dr Reddy’s slipped 0.32 percent on Wednesday, settling at Rs 1280.85 on the BSE.